BioSpace News Archive

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company today announced that the Company’s immuno-oncology product candidate, ALT-702, met a key pre-clinical efficacy milestone with the demonstration of systemic antitumor activity following intra-tumoral injection in an individual solid tumor.

VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the sale of DOCit, an innovative, cloud-based forms and task management mobile app for Long Term Care providers, to Caressant Care Nursing and Retirement Homes Limited (“Caressant Care”).

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Health Canada has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Inlyta® (axitinib), a tyrosine kinase inhibitor, for first-line treatment of patients with advanced renal cell carcinoma (RCC)

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, commemorates the first International Alagille Awareness Day on January 24, 2020, acknowledging pediatric hepatologist and researcher Dr. Daniel Alagille, who first characterized the syndrome

Legato Healthcare Marketing announces the launch of its new publication division, equipped to produce customized printed and digital magazines within and outside of the healthcare industry.

Microvi Biotech Inc. announced today that they will be installing a Microvi MNE nitrate treatment system for Hillview Water in Raymond, CA.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to its board of directors.

Global medical technology leader Hillrom (NYSE: HRC) and The UK Sepsis Trust today announced an exclusive, year-long partnership to raise greater awareness of sepsis. Throughout 2020 Hillrom will be working with The UK Sepsis Trust to provide awareness and training to hospitals on how they can use existing technology to help identify deteriorating patients more quickly.

LifeNet Health, the Virginia-based Organ Procurement Organization (OPO), facilitated a record 585 organ transplants in 2019, exceeding the previous year’s record of 497 transplants.

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock,